- freely available
Aberrant Signaling Pathways in Glioma
AbstractGlioblastoma multiforme (GBM), a WHO grade IV malignant glioma, is the most common and lethal primary brain tumor in adults; few treatments are available. Median survival rates range from 12–15 months. The biological characteristics of this tumor are exemplified by prominent proliferation, active invasiveness, and rich angiogenesis. This is mainly due to highly deregulated signaling pathways in the tumor. Studies of these signaling pathways have greatly increased our understanding of the biology and clinical behavior of GBM. An integrated view of signal transduction will provide a more useful approach in designing novel therapies for this devastating disease. In this review, we summarize the current understanding of GBM signaling pathways with a focus on potential molecular targets for anti-signaling molecular therapies.
Share & Cite This Article
Nakada, M.; Kita, D.; Watanabe, T.; Hayashi, Y.; Teng, L.; Pyko, I.V.; Hamada, J.-I. Aberrant Signaling Pathways in Glioma. Cancers 2011, 3, 3242-3278.View more citation formats
Nakada M, Kita D, Watanabe T, Hayashi Y, Teng L, Pyko IV, Hamada J-I. Aberrant Signaling Pathways in Glioma. Cancers. 2011; 3(3):3242-3278.Chicago/Turabian Style
Nakada, Mitsutoshi; Kita, Daisuke; Watanabe, Takuya; Hayashi, Yutaka; Teng, Lei; Pyko, Ilya V.; Hamada, Jun-Ichiro. 2011. "Aberrant Signaling Pathways in Glioma." Cancers 3, no. 3: 3242-3278.
Notes: Multiple requests from the same IP address are counted as one view.